A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes

Abstract Background Previous studies suggest that dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium glucose cotransporter 2 (SGLT2) inhibitors have different effects on the lipid profile in patients with type 2 diabetes. We investigated the effects of DPP-4 inhibitors and SGLT2 inhibitors on the...

Full description

Bibliographic Details
Main Authors:	Seon-Ah Cha, Yong-Moon Park, Jae-Seung Yun, Tae-Seok Lim, Ki-Ho Song, Ki-Dong Yoo, Yu-Bae Ahn, Seung-Hyun Ko
Format:	Article
Language:	English
Published:	BMC 2017-04-01
Series:	Lipids in Health and Disease
Subjects:	DPP-4 inhibitor SGLT2 inhibitor Lipid Type 2 diabetes
Online Access:	http://link.springer.com/article/10.1186/s12944-017-0443-4

Similar Items

Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
by: A Young Sim, et al.
Published: (2021-08-01)

Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis
by: Tamara Y. Milder, et al.
Published: (2019-01-01)

Combination therapy with SGLT2 inhibitors for diabetic kidney disease
by: Yuwen Cai, et al.
Published: (2020-07-01)

SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
by: Honghong Zou, et al.
Published: (2017-05-01)

SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by suppressing the activity of SGLT-2
by: Ying Zhou, et al.
Published: (2019-01-01)

SGLT-2 Inhibitors: Are They a Promising Treatment Option in T2DM Patients with NAFLD?
by: Dimitrios Patoulias
Published: (2018-04-01)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
by: Alex Ali Sayour, et al.
Published: (2021-09-01)

SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin
by: Santosh Kumar Singh, et al.
Published: (2014-01-01)

The Effects of SGLT2 Inhibitors on Lipid Metabolism
by: Zsolt Szekeres, et al.
Published: (2021-02-01)

Candida sepsis from local infection in a patient with a urostomy on SGLT2 inhibitor therapy
by: Ralph Wendt, et al.
Published: (2020-09-01)

SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy
by: Daiji Kawanami, et al.
Published: (2017-05-01)

A Fluorescent Glucose Transport Assay for Screening SGLT2 Inhibitors in Endogenous SGLT2-Expressing HK-2 Cells
by: Yan-Ting Lu, et al.
Published: (2018-11-01)

Is cancer incidence modified by SGLT2 inhibitors?
by: Lev M. Berstein
Published: (2019-10-01)

Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus
by: Hyun A Cho, et al.
Published: (2017-06-01)

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
by: Chiara Maria Assunta Cefalo, et al.
Published: (2019-02-01)

The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition
by: Muhammad Saad, et al.
Published: (2018-11-01)

Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients
by: In-Chang Hwang, et al.
Published: (2020-05-01)

SGLT2 inhibitors: a promising class of antidiabetic agents
by: Camelia DIACONU
Published: (2018-12-01)

SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
by: Swetha R. Kanduri, et al.
Published: (2020-08-01)

Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus
by: Leyna Leite Santos, et al.

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis
by: Hang-Long Li, et al.
Published: (2021-05-01)

Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
by: Derosa G, et al.
Published: (2018-09-01)

Are the Newer Antidiabetic Agents Worth the Cost?
by: Sudhakar Pemminati, et al.
Published: (2016-03-01)

Class effects of SGLT2 inhibitors on cardiorenal outcomes
by: Aaron Y. Kluger, et al.
Published: (2019-08-01)

Bitter sweet: Fournier’s Gangrene and SGLT2 inhibitors
by: Coralea Kappel
Published: (2019-12-01)

A cell-based fluorescent glucose transporter assay for SGLT2 inhibitor discovery
by: Yi Huan, et al.
Published: (2013-04-01)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
by: Jinglong Liu, et al.
Published: (2014-04-01)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
by: Simes BC, et al.
Published: (2019-10-01)

A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
by: Chang Hee Jung, et al.
Published: (2014-08-01)

Changes in glucose-induced plasma active glucagon-like peptide-1 levels by co-administration of sodium–glucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors in rodents
by: Takahiro Oguma, et al.
Published: (2016-12-01)

A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population
by: Shen L, et al.
Published: (2021-04-01)

SGLT2 inhibitors in T2D and associated comorbidities — differentiating within the class
by: Guntram Schernthaner, et al.
Published: (2019-06-01)

Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
by: Kai-Fan Tsai, et al.
Published: (2021-07-01)

SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy
by: Li N, et al.
Published: (2020-11-01)

Are the Cardiorenal Benefits of SGLT2 Inhibitors Due to Inhibition of the Sympathetic Nervous System?∗
by: Subodh Verma, MD, PhD
Published: (2020-02-01)

Treatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic Variations
by: Jasna Klen, et al.
Published: (2021-09-01)

SGLT2 inhibitors and lower limb complications: the diuretic-induced hypovolemia hypothesis
by: Louis Potier, et al.
Published: (2021-05-01)

Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy
by: Ayako Nagayama, et al.
Published: (2021-05-01)

Renoprotective Effects of DPP-4 Inhibitors
by: Daiji Kawanami, et al.
Published: (2021-02-01)